Soooo, excuse my ignorance on some of these matter
Post# of 36537
(Total Views: 286)
Posted On: 03/12/2020 2:04:21 PM
Soooo, excuse my ignorance on some of these matters... 2 Qs for the group:
1) What is in the Form 10 that cold not have come out sooner, perhaps more closely to the naming of the last board member? It seems to me, after a once-over, that this info was existing while we waited for the divs to clear and could have been issued sooner, especially since there is a 60 day waiting period.
2) There are 400MM shares. GNBT's holding ~362MM and Joe has about 3MM. That leaves the 35MM for us in the 2 spins... So we hold less than 10% of the shares.
So that would imply a huge value for NGIO, if we think me are still shooting for a $4/share NAS listing? And that would then leave GNBT with about 82MM shares to sell for working capital, deals, etc., if Joe wants to keep 70% internally.
The problem remains getting to the spin date, which appears to be summer time at the earliest. If we don't get a better SP to access the S-1 funding, close an Excellagen licensing deal, or pull off a win over Covid-19, where does the $ come from to stay in business, let alone close the AltuCell deal, etc.?
1) What is in the Form 10 that cold not have come out sooner, perhaps more closely to the naming of the last board member? It seems to me, after a once-over, that this info was existing while we waited for the divs to clear and could have been issued sooner, especially since there is a 60 day waiting period.
2) There are 400MM shares. GNBT's holding ~362MM and Joe has about 3MM. That leaves the 35MM for us in the 2 spins... So we hold less than 10% of the shares.
So that would imply a huge value for NGIO, if we think me are still shooting for a $4/share NAS listing? And that would then leave GNBT with about 82MM shares to sell for working capital, deals, etc., if Joe wants to keep 70% internally.
The problem remains getting to the spin date, which appears to be summer time at the earliest. If we don't get a better SP to access the S-1 funding, close an Excellagen licensing deal, or pull off a win over Covid-19, where does the $ come from to stay in business, let alone close the AltuCell deal, etc.?
(2)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼